How Does the Coronavirus Behave Inside a Patient?
We’ve counted the viral spread across peoples; now we need to count it within people.
Related Articles
DARZALEX® (daratumumab) receives the first positive CHMP opinion for patients with high-risk smouldering multiple myeloma
If approved, daratumumab will be the first authorised treatment option for patients with smouldering multiple myeloma at high-risk of developing multiple…
Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: a report of the Cancer Genomics Consortium Plasma Cell Neoplasm Working Group
Blood Cancer Journal – Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: a report of the Cancer Genomics…
Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: a report of the Cancer Genomics Consortium Plasma Cell Neoplasm Working Group
Blood Cancer Journal – Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: a report of the Cancer Genomics…
Global Oncology Trends 2025
The Global Oncology Trends 2025 report explores novel cancer therapies, rising expenditures, and access disparities. It highlights trends in ADCs, radioligand therapies, CAR-T, and spending…
Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma
Ciltacabtagene autoleucel (also known as cilta-cel) is a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA) on the surface of cancer…
Beyond maximum grade: advancing the measurement and analysis of adverse events in malignant haematology trials in the modern era
As the therapeutic landscape in haematological malignancies has evolved from traditional chemotherapies to novel biological, targeted, and cellular therapies, adverse event profiles have accordingly shifted…
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma
Despite significant improvements in survival of patients with multiple myeloma (MM), outcomes remain heterogeneous, and a significant proportion of patients experience suboptimal outcomes. Importantly, traditional…
International Myeloma Working Group
The International Myeloma Working Group (IMWG) emerged from the IMF’s Scientific Advisory Board which was established in 1995. It became clear that there was a…
Welcome! You are invited to join a webinar: Tratando o mieloma múltiplo refratário/recidivado (MM/RR): por onde começar?. After registering, you will receive a confirmation email about joining the webinar.
Moderação Dr. Nelson Hamerschlak Hematologista – Hospital Israelita Albert Einstein PALESTRANTE Dr. S. Vincent Rajkumar Hematologista – Mayo Clinic 04 de junho | 4º feira…
From No Hope to a Potential Cure for a Deadly Blood Cancer
Multiple myeloma is considered incurable, but a third of patients in a Johnson & Johnson clinical trial have lived without detectable cancer for years after…